Publicacións nas que colabora con M.ª Jesús Lamas Díaz (26)

2021

  1. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 5, pp. 2216-2227

  2. Therapeutic drug monitoring of voriconazole: Validation of a high performance liquid chromatography method and comparison with an ARK immunoassay

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 3, pp. 154-159

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

2019

  1. An Observational Study of the Efficacy and Safety of Voriconazole in a Real-Life Clinical Setting

    Journal of Chemotherapy, Vol. 31, Núm. 1, pp. 49-57

  2. Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: First single-centre, prospective, crossover study in patients

    International Journal of Pharmaceutics, Vol. 567

  3. Therapeutic approach in fungal keratitis

    Mycotic Keratitis (CRC Press), pp. 189-216

2018

  1. Longitudinal PET/CT evaluation of TNBS-induced inflammatory bowel disease rat model

    International Journal of Pharmaceutics, Vol. 549, Núm. 1-2, pp. 335-342

  2. Ophthalmic Econazole Hydrogels for the Treatment of Fungal Keratitis

    Journal of Pharmaceutical Sciences, Vol. 107, Núm. 5, pp. 1342-1351

  3. Preclinical characterization and clinical evaluation of tacrolimus eye drops

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 152-161

  4. Review of intraocular pharmacokinetics of anti-infectives commonly used in the treatment of infectious endophthalmitis

    Pharmaceutics, Vol. 10, Núm. 2

2017

  1. Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis

    Farmacia Hospitalaria, Vol. 41, Núm. 6, pp. 678-687

  2. Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging

    International Journal of Pharmaceutics, Vol. 528, Núm. 1-2, pp. 714-722

  3. In Vitro Evaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops

    Journal of Ocular Pharmacology and Therapeutics, Vol. 33, Núm. 3, pp. 202-209

  4. In vivo eye surface residence determination by high-resolution scintigraphy of a novel ion-sensitive hydrogel based on gellan gum and kappa-carrageenan

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 114, pp. 317-323

  5. Positron emission tomography for the development and characterization of corneal permanence of ophthalmic pharmaceutical formulations

    Investigative Ophthalmology and Visual Science, Vol. 58, Núm. 2, pp. 772-780

  6. Preclinical PET study of intravitreal injections

    Investigative Ophthalmology and Visual Science, Vol. 58, Núm. 7, pp. 2843-2851

2016

  1. Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the hospital pharmacy departments

    Farmacia Hospitalaria, Vol. 40, Núm. 5, pp. 352-370

  2. La optimización de las formulaciones magistrales oftálmicas en los servicios de farmacia hospitalaria

    El Farmacéutico. Hospitales, Núm. 207, pp. 4-14

  3. Ophthalmic formulations new goals

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria